8
Participants
Start Date
February 4, 2016
Primary Completion Date
February 10, 2017
Study Completion Date
February 2, 2020
huJ591
Antibody is derived from a hybridoma originally produced in the Weill Medical College Laboratory of Urological Oncology. Treatment with 100 mg of HuJ591 will be administered as an intravenous infusion at a concentration of 5 mg/mL and rate of \<5 mg/minute.
89Zr-J591
Drug product is manufactured by the radiochemistry staff of Citigroup Biomedical Imaging Center (CBIC) research core facility. Radiolabeling of DFO-huJ591 with 89Zr is achieved by the addition of 89Zr-oxalate to the DFO-huJ591 in ammonium acetate buffer.
Weill Cornell Medical College, New York
Weill Medical College of Cornell University
OTHER